MA52920B1 - Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f - Google Patents

Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Info

Publication number
MA52920B1
MA52920B1 MA52920A MA52920A MA52920B1 MA 52920 B1 MA52920 B1 MA 52920B1 MA 52920 A MA52920 A MA 52920A MA 52920 A MA52920 A MA 52920A MA 52920 B1 MA52920 B1 MA 52920B1
Authority
MA
Morocco
Prior art keywords
compositions
pyridinoylpiperidine
methods relating
ht1f agonists
ht1f
Prior art date
Application number
MA52920A
Other languages
English (en)
Other versions
MA52920A (fr
Inventor
Brigida Allieri
Paul Fagan
Emma Sharp
Raymond Skwierczynski
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52920(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of MA52920A publication Critical patent/MA52920A/fr
Publication of MA52920B1 publication Critical patent/MA52920B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux pseudo-polymorphes du sel d'hémisuccinate de 2,4,6-trifluoro-n-[6-(1-méthyl-pipéridine-4-carbonyle)-pyridin-2-yl]-benzamide qui sont utiles dans des compositions pharmaceutiques, par exemple, pour le traitement et la prévention de la céphalée migraineuse.
MA52920A 2016-12-06 2017-12-05 Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f MA52920B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430662P 2016-12-06 2016-12-06
PCT/US2017/064652 WO2018106657A1 (fr) 2016-12-06 2017-12-05 Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Publications (2)

Publication Number Publication Date
MA52920A MA52920A (fr) 2021-04-28
MA52920B1 true MA52920B1 (fr) 2021-11-30

Family

ID=60972336

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52920A MA52920B1 (fr) 2016-12-06 2017-12-05 Compositions et procédés se rapportant à des agonistes de pyridinoylpipéridine 5-ht1f

Country Status (38)

Country Link
US (1) US11053214B2 (fr)
EP (1) EP3551617B1 (fr)
JP (4) JP2020500936A (fr)
KR (4) KR20210102497A (fr)
CN (3) CN115385893A (fr)
AU (1) AU2017373784B2 (fr)
BR (1) BR112019010934A2 (fr)
CA (1) CA3043772C (fr)
CL (1) CL2019001426A1 (fr)
CO (1) CO2019005290A2 (fr)
CR (1) CR20190251A (fr)
CY (1) CY1124540T1 (fr)
DK (1) DK3551617T3 (fr)
DO (1) DOP2019000139A (fr)
EA (1) EA201991112A1 (fr)
EC (1) ECSP19040190A (fr)
ES (1) ES2889476T3 (fr)
HR (1) HRP20211557T1 (fr)
HU (1) HUE056820T2 (fr)
IL (1) IL266598B2 (fr)
JO (1) JOP20190129B1 (fr)
LT (1) LT3551617T (fr)
MA (1) MA52920B1 (fr)
MD (1) MD3551617T2 (fr)
MX (2) MX388091B (fr)
MY (1) MY196855A (fr)
NZ (1) NZ752906A (fr)
PE (2) PE20241297A1 (fr)
PH (1) PH12019501252B1 (fr)
PL (1) PL3551617T3 (fr)
PT (1) PT3551617T (fr)
RS (1) RS62415B1 (fr)
SI (1) SI3551617T1 (fr)
TN (1) TN2019000174A1 (fr)
TW (1) TWI671290B (fr)
UA (1) UA124433C2 (fr)
WO (1) WO2018106657A1 (fr)
ZA (1) ZA201903449B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI829107B (zh) 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
US12271057B1 (en) 2019-12-20 2025-04-08 The Uab Research Foundation Chromatic aberration tuning ophthalmic corrector lens methods
IL307949A (en) 2021-05-07 2023-12-01 Lilly Co Eli 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridine-2-ylg-benzamide hemisuccinate masked flavor compounds, and an orodispersible tablet consisting of the same
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2011123654A1 (fr) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions et méthodes de synthèse d'agonistes des récepteurs 5-ht1f dérivés de la pyridinoylpipéridine
WO2012163365A1 (fr) 2011-06-01 2012-12-06 Concit Pharma Aps Combinaisons d'agonistes de récepteur de sérotonine pour le traitement de troubles du mouvement
CN113149959A (zh) 2016-07-15 2021-07-23 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
SI3551617T1 (sl) 2021-11-30
PT3551617T (pt) 2021-10-04
CN110291079A (zh) 2019-09-27
CA3043772C (fr) 2022-06-07
JOP20190129B1 (ar) 2023-03-28
JP2024178323A (ja) 2024-12-24
MA52920A (fr) 2021-04-28
MX392547B (es) 2025-03-24
EP3551617A1 (fr) 2019-10-16
DOP2019000139A (es) 2019-08-15
ECSP19040190A (es) 2019-08-30
PH12019501252B1 (en) 2024-05-24
EA201991112A1 (ru) 2019-10-31
KR20230008257A (ko) 2023-01-13
HRP20211557T1 (hr) 2022-01-07
AU2017373784A1 (en) 2019-05-16
MY196855A (en) 2023-05-05
KR20250070124A (ko) 2025-05-20
PH12019501252A1 (en) 2019-12-02
HUE056820T2 (hu) 2022-03-28
TWI671290B (zh) 2019-09-11
JP2020500936A (ja) 2020-01-16
CN115385893A (zh) 2022-11-25
PE20191134A1 (es) 2019-09-02
CA3043772A1 (fr) 2018-06-14
CN115385894A (zh) 2022-11-25
DK3551617T3 (da) 2021-09-13
US20200087279A1 (en) 2020-03-19
KR20210102497A (ko) 2021-08-19
PL3551617T3 (pl) 2021-12-20
BR112019010934A2 (pt) 2019-10-01
CL2019001426A1 (es) 2019-10-11
TW201833097A (zh) 2018-09-16
IL266598B1 (en) 2024-01-01
IL266598A (en) 2019-07-31
RS62415B1 (sr) 2021-10-29
ES2889476T3 (es) 2022-01-12
AU2017373784B2 (en) 2020-04-23
MD3551617T2 (ro) 2021-12-31
CO2019005290A2 (es) 2019-05-31
UA124433C2 (uk) 2021-09-15
IL266598B2 (en) 2024-05-01
MX388091B (es) 2025-03-19
EP3551617B1 (fr) 2021-08-11
PE20241297A1 (es) 2024-06-24
US11053214B2 (en) 2021-07-06
CY1124540T1 (el) 2022-07-22
JP2022000451A (ja) 2022-01-04
LT3551617T (lt) 2021-10-11
MX2021014139A (es) 2022-05-24
NZ752906A (en) 2021-07-30
JOP20190129A1 (ar) 2019-05-29
TN2019000174A1 (en) 2020-10-05
WO2018106657A1 (fr) 2018-06-14
MX2019006520A (es) 2019-08-21
JP7561240B2 (ja) 2024-10-03
JP7818666B2 (ja) 2026-02-20
ZA201903449B (en) 2021-02-24
KR20190075130A (ko) 2019-06-28
JP2023123678A (ja) 2023-09-05
CR20190251A (es) 2019-08-26

Similar Documents

Publication Publication Date Title
ZA202502751B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MA62580B1 (fr) Amines bicycliques utilisées en tant qu'inhibiteurs de cdk2
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MX381787B (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos.
MX388091B (es) Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
JOP20170102B1 (ar) أشكال بلورية منn- [2-(3-هيدروكسي-3-مثيل بيوتيل)-6-(2-هيدروكسي بروبان-2-يل)-2h-إندازول-5-يل]-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
CR20200027A (es) Agentes, usos y métodos para el tratamiento
EP3597198A4 (fr) Composition pour traitement des maladies articulaires, et kit contenant cette composition
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
EA202091524A1 (ru) Ингибиторы рецептора, активируемого протеазой 2
EP3603647A4 (fr) Composition pharmaceutique pour la prévention et le traitement du glaucome, contenant un dérivé d'adénosine
EP3976111A4 (fr) Procédés et compositions pour le traitement du cancer mettant en oeuvre des vecteurs de médicaments se liant au collagène
MX2021007967A (es) Inhibidores de síntesis de leucotrienos.
EP3597199A4 (fr) Composition pour traitement des maladies articulaires, et kit contenant cette composition
MA51297B1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14
MX374114B (es) Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.
MA45905B1 (fr) Composition pour traiter une blépharite contenant du terpinène-4-ol
MA39227B1 (fr) Amides hétéroaryles comme inhibiteurs de l'agrégation protéique
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств